Table 4.
Antiviral effects of GS-9669 in combination with other anti-HCV drugs in GT 1b replicon cells
| Drug combined with GS-9669 | Antiviral mechanism | Mean synergy volume (nM2) ± SDa | Mean antagonism volume (nM2) ± SDa | Interaction |
|---|---|---|---|---|
| GS-5885 | NS5A | 34 ± 19 | 0 ± 0 | Minor synergy |
| GS-9451 | NS3 protease | 19 ± 13 | −2 ± 2 | Additive |
| GS-9256 | NS3 protease | 22 ± 12 | −7 ± 7 | Additive |
| Tegobuvir | NS5B NNI | 70 ± 26 | 0 ± 0 | Moderate synergy |
| GS-6620 | NS5B nucleotide | 26 ± 28 | −1 ± 3 | Minor synergy |
| IFN-α | 31 ± 23 | −2 ± 4 | Minor synergy | |
| RBV | 12 ± 8 | −12 ± 9 | Additive |
a
Values represent the means ± standard deviations of data from two independent experiments performed in triplicate.